BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2530799)

  • 1. The pharmacokinetics of paroxetine in patients with liver cirrhosis.
    Krastev Z; Terziivanov D; Vlahov V; Maleev A; Greb WH; Eckl KM; Dierdorf HD; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():91-2. PubMed ID: 2530799
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacokinetics of paroxetine in renal impairment.
    Doyle GD; Laher M; Kelly JG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():89-90. PubMed ID: 2530798
    [No Abstract]   [Full Text] [Related]  

  • 3. Ability of charcoal to prevent absorption of paroxetine.
    Greb WH; Buscher G; Dierdorf HD; von Schrader HW; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():156-7. PubMed ID: 2530777
    [No Abstract]   [Full Text] [Related]  

  • 4. The pharmacokinetics of paroxetine in the elderly.
    Bayer AJ; Roberts NA; Allen EA; Horan M; Routledge PA; Swift CG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():85-6. PubMed ID: 2530796
    [No Abstract]   [Full Text] [Related]  

  • 5. Absorption of paroxetine under various dietary conditions and following antacid intake.
    Greb WH; Brett MA; Buscher G; Dierdorf HD; von Schrader HW; Wolf D; Mellows G; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():99-101. PubMed ID: 2530802
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.
    Greb WH; Buscher G; Dierdorf HD; Köster FE; Wolf D; Mellows G
    Acta Psychiatr Scand Suppl; 1989; 350():95-8. PubMed ID: 2530801
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites.
    Haddock RE; Johnson AM; Langley PF; Nelson DR; Pope JA; Thomas DR; Woods FR
    Acta Psychiatr Scand Suppl; 1989; 350():24-6. PubMed ID: 2530779
    [No Abstract]   [Full Text] [Related]  

  • 9. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.
    Tasker TC; Kaye CM; Zussman BD; Link CG
    Acta Psychiatr Scand Suppl; 1989; 350():152-5. PubMed ID: 2530776
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.
    Bannister SJ; Houser VP; Hulse JD; Kisicki JC; Rasmussen JG
    Acta Psychiatr Scand Suppl; 1989; 350():102-6. PubMed ID: 2530759
    [No Abstract]   [Full Text] [Related]  

  • 11. A pharmacokinetic dose titration study in adult and elderly depressed patients.
    Hebenstreit GF; Fellerer K; Zöchling R; Zentz A; Dunbar GC
    Acta Psychiatr Scand Suppl; 1989; 350():81-4. PubMed ID: 2530795
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the metabolism and pharmacokinetics of paroxetine in man.
    Kaye CM; Haddock RE; Langley PF; Mellows G; Tasker TC; Zussman BD; Greb WH
    Acta Psychiatr Scand Suppl; 1989; 350():60-75. PubMed ID: 2530793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical pharmacology of paroxetine in healthy subjects.
    Raptopoulos P; McClelland GR; Jackson D
    Acta Psychiatr Scand Suppl; 1989; 350():46-8. PubMed ID: 2530788
    [No Abstract]   [Full Text] [Related]  

  • 14. Regional distribution of serotonergic pre- and postsynaptic markers in human brain.
    Laruelle M; Maloteaux JM
    Acta Psychiatr Scand Suppl; 1989; 350():56-9. PubMed ID: 2530792
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of paroxetine in patients with cirrhosis.
    Dalhoff K; Almdal TP; Bjerrum K; Keiding S; Mengel H; Lund J
    Eur J Clin Pharmacol; 1991; 41(4):351-4. PubMed ID: 1839532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline.
    Kuhs H; Schlake HP; Rolf LH; Rudolf GA
    Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine: pharmacokinetic and antidepressant effect in the elderly.
    Lundmark J; Scheel Thomsen I; Fjord-Larsen T; Manniche PM; Mengel H; Møller-Nielsen EM; Pauser H; Wålinder J
    Acta Psychiatr Scand Suppl; 1989; 350():76-80. PubMed ID: 2530794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements.
    Nielsen OA; Morsing I; Petersen JS; Larsen T; Møller SE; Manniche PM; Skausig OB
    Acta Psychiatr Scand; 1991 Sep; 84(3):233-41. PubMed ID: 1835251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet 3H-paroxetine binding in depressed patients.
    D'haenen H; De Waele M; Leysen JE
    Psychiatry Res; 1988 Oct; 26(1):11-7. PubMed ID: 2976947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.